Latest News & Blog

THINKING

Welcome to Well Filtered™

A blog series dedicated to unearthing the ideas, perspectives, and innovations that matter most in kidney health.

NEWS

• Renalytix plc successful completion of $30.0 million financing package 04.08.22

  Director/PDMR Dealing NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, JAPAN, THE REPUBLIC OF SOUTH AFRICA, NEW ZEALAND OR IN OR INTO ANY OTHER JURISDICTION IN WHICH OFFERS OR SALES WOULD BE PROHIBITED BY

  
  Read More
• Renalytix plc Issue of shares 04.08.22

  NEW YORK and SALT LAKE CITY, April 08, 2022 (GLOBE NEWSWIRE) -- Renalytix Plc (NASDAQ: RNLX) (LSE: RENX) announces that under the Company's Employee Share Purchase Plan (the "ESPP"), 22,814 new ordinary shares of £0.0025 each in the capital of the Company (the "Ordinary Shares") have been issued to

  
  Read More
• Renalytix announces a $30.0 million financing package 03.31.22

  NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, JAPAN, THE REPUBLIC OF SOUTH AFRICA, NEW ZEALAND OR IN OR INTO ANY OTHER JURISDICTION IN WHICH OFFERS OR SALES WOULD BE PROHIBITED BY APPLICABLE LAW.

  
  Read More
• Renalytix Reports Financial Results for Second Quarter of Fiscal Year 2022 03.31.22

  LONDON and SALT LAKE CITY, March 31, 2022 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care, today

  
  Read More
• Confirmation of Appointment of Timothy Scannell to Renalytix Board of Directors 03.30.22

  NEW YORK and SALT LAKE CITY, March 30, 2022 (GLOBE NEWSWIRE) -- Renalytix Plc (NASDAQ: RNLX) (LSE: RENX) today announced that, following the Company’s announcement on February 22, 2022, Timothy Scannell has been appointed to the Board as an independent Non-Executive Director of Renalytix.   As an

  
  Read More
• Renalytix Reaches Enrollment Milestone for Building KidneyIntelX as Premier Precision Medicine Platform for Kidney Disease and Diabetes 03.29.22

  KidneyIntelX RAPID biobank program and partners on track to reach over 30,000 biospecimens with matched electronic health records from multiple centers across the U.S. NEW YORK and SALT LAKE CITY, March 29, 2022 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) today announced the

  
  Read More
• Renalytix to Report Second Quarter and First Half Fiscal Year 2022 Financial Results on March 31 03.25.22

  NEW YORK and SALT LAKE CITY, March 25, 2022 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) today announced the Company will release its second quarter and first half fiscal year 2022 financial results on Thursday, March 31, 2022, before market open.

  
  Read More
• Renalytix Launches myIntelX, Providing National Physician Access to KidneyIntelX Testing Platform 03.09.22

  
  Read More
• KidneyIntelX™ Clinical Results Presented at World Congress of Nephrology Demonstrate Improved Prediction of Kidney Function Over Standard of Care 02.24.22

  
  Read More
• Renalytix to Present at Cowen 42nd Annual Health Care Conference 02.22.22

  NEW YORK and SALT LAKE CITY, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) (“Renalytix” or the “Company”) today announced the Company will be presenting at the upcoming virtual Cowen 42 nd Annual Health Care Conference. Renalytix’s management is scheduled to participate

  
  Read More

• 1
• 2
• 3
• 4
• 5
• 6
...
• 10
• >>